Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CADL
DateTimeSourceHeadlineSymbolCompany
24/05/202421:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
24/05/202407:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
24/05/202407:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
22/05/202422:00GlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
20/05/202422:00GlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
14/05/202422:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
14/05/202422:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
14/05/202422:00GlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial ResultsĀ and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
25/04/202422:00GlobeNewswire Inc.Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
11/04/202423:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
09/04/202422:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsNASDAQ:CADLCandel Therapeutics Inc
04/04/202423:00GlobeNewswire Inc.Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
29/03/202407:05GlobeNewswire Inc.Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
28/03/202423:05GlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
07/03/202400:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
06/03/202408:30GlobeNewswire Inc.Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateNASDAQ:CADLCandel Therapeutics Inc
14/02/202401:00Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
13/02/202423:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
13/02/202423:30GlobeNewswire Inc.CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
06/02/202400:00GlobeNewswire Inc.Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsNASDAQ:CADLCandel Therapeutics Inc
20/01/202400:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
13/01/202408:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
04/01/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
13/12/202300:58Dow Jones NewsCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409NASDAQ:CADLCandel Therapeutics Inc
13/12/202300:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
13/12/202300:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
01/12/202309:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
01/12/202309:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
01/12/202309:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
29/11/202308:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CADL